Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Business Wire
Ikonisys SA: Hospitex International Launches Urine24, the First-Online Urinary Cytology Test Platform, Marking a Breakthrough in Early Bladder Cancer Diagnosis in Italy
Business Wire
6 min read

In This Article:

FLORENCE, Italy & PARIS, April 03, 2025--(BUSINESS WIRE)--Regulatory News:

ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), announces that its Italian subsidiary Hospitex International has launched Urine24.com, the first online-available urinary cytology test for early bladder cancer diagnosis. The service is now available through its official website offering a non-invasive, fast, and highly reliable solution for millions of Italians.

Urine24 to Address a Critical Need in the Italian Market

In Italy, bladder cancer is one of the most common malignancies, with approximately 29,200 new cases diagnosed annually and a patient population of over 313,000. The need for precise and efficient screening tools is therefore a top priority. With a retail price of €68 per test, the potential market for Urine24 in Italy exceeds €23 million annually, considering both new cases and the monitoring of recurrences, which occur in 60-70% of patients.

The test is recommended for individuals at higher risk of developing bladder cancer, including:

  • Smokers, the leading risk factor for this malignancy (approximately 8.6 million Italians);

  • Workers exposed to chemicals, such as dyes, paints, industrial solvents, and pesticides;

  • People with chronic urinary infections or a history of recurrent cystitis;

  • Individuals with a family history of urothelial tumors;

  • Those who have undergone radiation or chemotherapy treatments in the pelvic area;

  • All individuals over the age of 50, a group with a significantly increased risk of developing bladder cancer (approximately 21.3 million Italians).

Considering smokers and individuals over 50, the potential target population for Urine24 in Italy is approximately 29.9 million people. If even 1% of this population were to take the test annually, the potential market would be around €20.4 million per year, highlighting the urgent need for accessible, early and effective diagnostic solutions for prevention of bladder cancer.

Urine24: A Game-Changer in Bladder Cancer Screening

Urine24 stands out for its use of advanced cytological technologies that allow the detection of cancerous cells in urine with high sensitivity and specificity. Urinary cytology is a well-established diagnostic test, but with Urine24, it is performed using a thin-layer method, which enhances sample quality, reduces false negatives, and increases result accuracy. Additionally, test interpretation follows The Paris System, an internationally standardized classification system that optimizes the identification of cellular abnormalities, providing clearer and more reliable results.

Terms and Privacy Policy
Your Privacy Choices
Utah Privacy Notice
More Info

Recommended Stories